Eli Lilly (LLY)

SpaceX has attractive prospects, but the market has already factored that into its share price.

Omada Health (NASDAQ:OMDA) highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic conditions, deepen channel partnerships and use GLP-1-related demand to broaden customer relationships

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

One of its more popular products just got the green light from a major national regulator.

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start.

It's not much of a rivalry yet.

XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% dividend.

Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered gr

XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns.

Can anyone take the top spot away from Eli Lilly in the anti-obesity area?

Berobenatide is one of the keys to Pfizer's future.

Jim Cramer praises Lockheed Martin and Ameriprise Financial, advises against Cipher Digital. Eli Lilly to acquire AtaiBeckley for $3.8B.

Sector ETFs give the impression of diversification. Most of them don't have it.

Some of America's largest growth stocks had a sluggish start to 2026, but they're bouncing back.

The drugmaker continues to face headwinds.

CVS Health (NYSE:CVS) reported second-quarter results that exceeded its expectations, citing earnings growth across all operating segments and raising its full-year outlook for adjusted earnings per share and operating cash flow. Chair and Chief Executive Officer David Joyner said the company gener

Global Abemaciclib Market to Reach USD 3.18 Billion by 2034, Growing at 9.7% CAGR According to the latest market intelligence from Intel Market Research, t

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 47.7% year on year to ...

Demand for the healthcare leader's weight-loss drugs continues to rise.

XLV's lower costs and broader holdings delivered 30% more growth over five years, while BBH's concentrated biotech focus offers higher single-stock upside.

On Aug. 5, 2026, new highs across major indexes reflect renewed confidence in global trade as investor confidence starts to return.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.5% in the morning session after the company delivered a massive "beat an...